Maintenance Notice (4:30 AM - 11:00 AM December 21, 2024): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 51037-30-0 | Product Number: M2053
Acipimox
×
![]()
×
Purity: >98.0%(GC)
Synonyms:
- 2-Carboxy-5-methylpyrazine 4-Oxide
- 5-Carboxy-2-methylpyrazine 1-Oxide
- 5-Methylpyrazine-2-carboxylic Acid 4-Oxide
Product Documents:
| Size | Unit Price | Belgium | Japan* |
|---|---|---|---|
| 1G |
55,00 €
|
2 | 2 |
| 5G |
176,00 €
|
Contact Us | 18 |
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | M2053 |
| Purity / Analysis Method | >98.0%(GC) |
| Molecular Formula / Molecular Weight | C__6H__6N__2O__3 = 154.13 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 51037-30-0 |
| Reaxys Registry Number | 777471 |
| PubChem Substance ID | 135726995 |
| Merck Index (14) | 111 |
| MDL Number | MFCD00865757 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
Properties (reference)
| Melting Point | 180 °C |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H319 : Causes serious eye irritation. |
| Precautionary Statements | P264 : Wash skin thoroughly after handling. P280 : Wear eye protection/ face protection. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
Related Laws:
| EC Number | 256-928-3 |
| RTECS# | UQ2453000 |
Transport Information:
| HS Number | 2933998090 |
Application
Acipimox: A Long-Acting Antilipemic Agent
Acipimox, a nicotic acid [N0082] analogue, is a long-acting antilipemic agent. It inhibits the release of non-esterified fatty acids from adipose tissue and reduces total serum triglyceride and cholesterol levels. These decrease occur in the in the very low density lipoprotein (VLDL) fraction and in the low density lipoprotein (LDL) fraction. In addition, acipimox increases high density lipoprotein (HDL) cholesterol. It is also reported to improve insulin sensitivity in diabetes. It is reported that acipimox acts on the nicotinic acid receptor, inhibiting the enzyme triglyceride lipase. (The product is for research purpose only.)
References
- Inhibition of lipolysis by nicotinic acid and by acipimox
- Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes
- Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects
- Molecular identification of high and low affinity receptors for nicotinic acid
- Nicotinic Acid Receptor Agonists (a review)
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.